Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 92.68 percent increase over losses of $(0.41) per share from the same period last year. The company reported quarterly sales of $50.025 million which beat the analyst consensus estimate of $48.607 million by 2.92 percent. This is a 613.22 percent increase over sales of $7.014 million the same period last year.